Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease

Rencz, Fanni; Lakatos, László; Gulàcsi, László; Brodszky, Valentin; Kürti, Zsuzsanna; Lovas, Szilvia; Banai, János; Herszényi, László; Cserni, Tamás; Molnár, Tamás; Péntek, Márta; Palatka, Károly

doi:10.1007/s11136-018-2003-4

Cited by 50 publications

(55 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We suggest considering the use of the EQ‐5D‐5L version (with five‐level response scale) to explore sHE in future studies [30]. The EQ‐5D‐5L has been proved to have better measurement properties as a health status measure than the EQ‐5D‐3L [10], and we expect an increase in its use in CD registries and clinical studies. We used the tariffs of the UK to calculate actual and expected EQ‐5D‐3L scores due to lack of local tariffs at the time of the analyses.…”

Section: Discussionmentioning

confidence: 99%

Subjective expectations regarding longevity and future health: a cross‐sectional survey among patients with Crohn's disease

et al. 2020

View full text Add to dashboard Cite

Aim The aim was to explore the subjective health expectations (sHE) of patients with Crohn's disease (CD) for both the near future and the elderly. Method A cross‐sectional survey was performed in four gastroenterology centres in Hungary. Consecutive outpatients with CD with age ≥ 18 were recruited. Socio‐demographic and disease characteristics were recorded and the Crohn's Disease Activity Index (CDAI), Perianal Disease Activity Index, Patients' Global Assessment (PGA) and current pain visual analogue scale (VAS) were assessed. Subjective life expectancy (sLE) was explored and compared to statistical life expectancy. Current health and sHE for 1 year ahead and for ages 60/70/80/90 were assessed using the descriptive system of the EQ‐5D‐3L. Results In all, 206 patients (54.9% men) with a mean age of 34.7 (SD 10.5 years) and disease duration of 10.5 (SD 6.3) years were studied. The CDAI score was 110.5 (SD 77.0) and 66% were treated by biologic drugs. Mean current EQ‐5D‐3L score was 0.80 (SD 0.17) and patients expected a 0.05 (SD 0.15) improvement within a year (P < 0.05). For ages 60/70/80/90, a mean EQ‐5D‐3L score of 0.59, 0.38, 0.10 and −0.12 respectively was provisioned. Age, current health status, sLE, PGA and pain VAS showed significant correlation with both 1‐year and older age sHE (P < 0.05). Long‐term sHE and sLE were negatively affected by the presence of extraintestinal manifestations but not by previous CD‐related surgery. Conclusion Patients with CD expect severe deterioration in health in later life. Given that unrealistic sHE may affect patients' current quality of life and health behaviour, we encourage physicians to explore and consider CD patients' sHE in clinical care.

show abstract

Section: Discussionmentioning

confidence: 99%

Subjective expectations regarding longevity and future health: a cross‐sectional survey among patients with Crohn's disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In terms of studies comparing the measurement properties of 3L and 5L versions of EQ-5D, many studies have been carried out across other populations [16]. Most of these studies showed that the 5L is highly consistent with 3L responses, as well as offering a better level of performance in terms of reduced ceiling effects and better informativity compared to the 3L [16][17][18]. Ceiling effects occur when a high proportion of subjects have maximum scores on the measurement of interest.…”

Section: Introductionmentioning

confidence: 99%

Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

Bhadhuri

Kind

Salari

et al. 2020

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background The EQ-5D-3L and EQ-5D-5L are two generic health-related quality of life measures, which may be used in clinical and health economic research. They measure impairment in 5 aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The aim of this study was to assess the performance of the EQ-5D-3L and EQ-5D-5L in measuring the self-reported health status of older patients with substantial multimorbidity and associated polypharmacy. Methods Between 2017 and 2019, we administered EQ-5D-3L and EQ-5D-5L to a subset of patients participating in the OPERAM trial at 6 months and 12 months after enrolment. The OPERAM trial is a two-arm multinational cluster randomised controlled trial of structured medication review assisted by a software-based decision support system versus usual pharmaceutical care, for older people (aged ≥ 70 years) with multimorbidity and polypharmacy. In the psychometric analyses, we only included participants who completed the measures in full at 6 and 12 months. We assessed whether responses to the measures were consistent by assessing the proportion of EQ-5D-5L responses, which were 2 or more levels away from that person’s EQ-5D-3L response. We also compared the measures in terms of informativity, and discriminant validity and responsiveness relative to the Barthel Index, which measures independence in activities of daily living. Results 224 patients (mean age of 77 years; 56% male) were included in the psychometric analyses. Ceiling effects reported with the EQ-5D-5L (22%) were lower than with the EQ-5D-3L (29%). For the mobility item, the EQ-5D-5L demonstrated better informativity (Shannon’s evenness index score of 0.86) than the EQ-5D-3L (Shannon’s evenness index score of 0.69). Both the 3L and 5L versions of EQ-5D demonstrated good performance in terms of discriminant validity, i.e. (out of all items of the EQ-5D-3L and EQ-5D-5L, the pain/discomfort and anxiety/depression items had the weakest correlation with the Barthel Index. Both the 3L and 5L versions of EQ-5D demonstrated good responsiveness to changes in the Barthel Index. Conclusion Both EQ-5D-3L and EQ-5D-5L demonstrated validity and responsiveness when administered to older adults with substantial multimorbidity and polypharmacy who were able to complete the measures.

show abstract

“…As indicated by Buchholz et al [27], most of the study populations are disease specific: inpatient rehabilitation [29], orthopaedics [30,31], stroke [32,33], liver disease [34][35][36], cancer [37], lung cancer [38], diabetes [39,40], dermatology [41], psoriasis [42] and mixed population [43]. Recently published studies comparing EQ-5D-3L and EQ-5D-5L also refer to the disease-specific subpopulations: cataract [44], Crohns disease [45] and hip replacement surgery [46]. However, disease-specific populations characterise by predictively worse health and resulting HRQoL, so the distribution of assessed health states in these groups is shifted compared to the distribution in the general population.…”

Section: Introductionmentioning

confidence: 99%

Validity of the EQ-5D-5L questionnaire among the general population of Poland

Młyńczak

Golicki

2020

Qual Life Res

View full text Add to dashboard Cite

Purpose We aim to compare the psychometric properties of the EQ-5D-5L questionnaire with the EQ-5D-3L version and EQ VAS, based on a survey conducted in a sample representing the general adult population of Poland. Methods The survey comprised health-related quality of life (HRQoL) questionnaires: EQ-5D-5L, EQ VAS, SF-12 and EQ-5D-3L, together with demographic and socio-economic characteristics items. The EQ-5D index values were estimated based on a directly measured value set for Poland. The following psychometric properties were analysed: feasibility, distribution of responses, redistribution from EQ-5D-3L to EQ-5D-5L, inconsistencies, ceiling effects, informativity power and construct validity. We proposed a novel approach to the construct validity assessment, based on the use of a machine learning technique known as the random forest algorithm. Results From March to June 2014, 3978 subjects (aged 18–87, 53.2% female) were surveyed. The EQ-5D-5L questionnaire had a lower ceiling effect compared to EQ-5D-3L (38.0% vs 46.6%). Redistribution from EQ-5D-3L to EQ-5D-5L was similar for each dimension, and the mean inconsistency did not exceed 5%. The results of known-groups validation confirmed the hypothesis concerning the relationship between the EQ-5D index values and age, sex and occurrence of diabetes. Conclusions The EQ-5D-5L, in comparison with its EQ-5D-3L equivalent, showed similar or better psychometric properties within the general population of a country. We assessed the construct validity of the questionnaire with a novel approach that was based on a machine learning technique known as the random forest algorithm.

show abstract

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease

Cited by 50 publications

References 64 publications

Subjective expectations regarding longevity and future health: a cross‐sectional survey among patients with Crohn's disease

Subjective expectations regarding longevity and future health: a cross‐sectional survey among patients with Crohn's disease

Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

Validity of the EQ-5D-5L questionnaire among the general population of Poland

Contact Info

Product

Resources

About